Novo Nordisk A/S to Issue Dividend of $1.28 (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) announced a dividend on Wednesday, February 4th. Shareholders of record on Monday, March 30th will be paid a dividend of 1.2751 per share on Wednesday, April 8th. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th.

Novo Nordisk A/S has increased its dividend by an average of 0.2%per year over the last three years. Novo Nordisk A/S has a payout ratio of 17.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Novo Nordisk A/S to earn $4.66 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 17.6%.

Novo Nordisk A/S Trading Down 6.5%

NVO traded down $3.06 during mid-day trading on Thursday, hitting $44.13. The stock had a trading volume of 31,101,247 shares, compared to its average volume of 25,472,236. The stock’s fifty day simple moving average is $53.75 and its 200-day simple moving average is $54.13. The firm has a market capitalization of $197.06 billion, a price-to-earnings ratio of 12.84 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 4th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company actions that support shareholder returns: Novo initiated a 2026 share‑repurchase programme (overall up to DKK 15bn; an initial DKK 3.8bn tranche started 4 Feb). This is a defensive measure to support the share price and offset weak near‑term growth. Share repurchase programme
• Positive Sentiment: Dividend declared (record date Mar 30) — incremental cash return that may partially cushion investor sentiment. (Company notice provided to investors.)
• Neutral Sentiment: Q4 results beat expectations on revenue and EPS, showing continued demand for obesity care, but the beat was overshadowed by downbeat 2026 guidance. Q4 earnings & call slides
• Negative Sentiment: Weak FY‑2026 guidance: management forecast a 5%–13% decline in sales and operating profit at constant currency, citing U.S. price cuts, margin pressure and competitive losses — the primary catalyst for the stock selloff. Guidance shock
• Negative Sentiment: Compounding further price pressure, telehealth player Hims & Hers said it will offer a compounded version of the Wegovy pill at $49/month (vs. Novo’s $149 branded pill), intensifying a price war and raising fears of margin erosion and faster commoditization. Hims & Hers Wegovy copy
• Negative Sentiment: Competitive dynamics: Eli Lilly’s stronger 2026 outlook and manufacturing scale have shifted investor preference toward Lilly, while Novo is portrayed as facing a “gap year” as it ramps capacity — a structural concern for market share and pricing power. Metabolic market split
• Negative Sentiment: Product‑specific headwinds: Ozempic sales in greater China declined for the first time last year, highlighting regional competition and the global reach of pricing/competitive pressures. Ozempic China sales drop

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.